BAM
EDIT icon

Belpointe Asset Management’s Editas Medicine EDIT Stock Holding History

Belpointe Asset Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-879
Closed -$6.37K – 1330
2023
Q1 		$6.37K Sell
879
-1,560
-64% -$13.9K ﹤0.01% 2921
2022
Q4 		$21.6K Buy
+2,439
New +$26.8K ﹤0.01% 2128
2021
Q3 		– Sell
-2,632
Closed -$149K – 1186
2021
Q2 		$149K Buy
2,632
+72
+3% +$2.66K 0.01% 951
2021
Q1 		$108K Hold
2,560
– – 0.01% 972
2020
Q4 		$179K Buy
+2,560
New +$105K 0.02% 733

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Belpointe Asset Management's EDIT Position: Q2 2023 in Review

Belpointe Asset Management sold out of Editas Medicine (EDIT) in Q2 2023, closing a stake of 879 shares — an estimated $6.37K sold.

Belpointe Asset Management first reported a position in EDIT in Q4 2020 and held it in 5 quarters. The position peaked at $179K in Q4 2020. 237 funds tracked by Wall St. Rank hold EDIT as of Q2 2023.

  • Belpointe Asset Management reported no remaining Editas Medicine position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 879 Editas Medicine shares in Q2 2023, an estimated $6.37K.
  • Belpointe Asset Management first reported a position in Editas Medicine in Q4 2020 and held it in 5 quarters.
  • Belpointe Asset Management's Editas Medicine position peaked at $179K in Q4 2020.
  • 237 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.